Review articleThe duodenal-jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type 2 diabetes
Section snippets
The duodenal-jejunal bypass sleeve
The duodenal-jejunal bypass sleeve (DJBS, EndoBarrier Gastrointestinal Liner; GI Dynamics Inc., Lexington, MA) is an endoscopically and fluoroscopically inserted implant (Fig. 1). It is an impermeable fluoropolymer sleeve that is reversibly fixated to the duodenal bulb and extends 80 cm into the small bowel, usually terminating in the proximal jejunum [3]. It allows transit of chyme from the stomach through to the jejunum without contact with the duodenal wall. Biliary and pancreatic fluids
Efficacy and safety
As would be expected for a technology in its infancy, there are only a handful of reported series regarding the use of the EndoBarrier in the literature (Table 1). They have all used excess weight loss (EWL) as their primary outcome measure. The first reported human case series was by Rodriguez et al. in 2008, which reported a 12-week EWL of 23.6% [5]. Four other studies, which are also shown in Table 1, have completed trials with the EndoBarrier in a randomized fashion against either sham
The future
The first series published on the use of the EndoBarrier uncovered a resolution of type 2 diabetes mellitus in 3 of 4 affected patients [5]. Interestingly, there was no difference in weight loss between diabetic and nondiabetic patients. This, therefore, brought up the possible role of the EndoBarrier in treating type 2 diabetes mellitus independently of weight loss. This notion has been substantiated this year by a team in Brazil that carried out an investigation into the use of the
Conclusion
The duodenal-jejunal bypass sleeve is the first endoluminal device to effectively cause weight loss through malabsorption in obese individuals. Its use is associated with difficulties regarding implantation as well as complications requiring early extraction. These will be reduced with increased use of the device. The application of the device in reported studies have primarily used 12-week EWL as a primary endpoint, so, at this stage, one must consider it only as a method of inducing temporary
Disclosures
The authors have no commercial associations that might be a conflict of interest in relation to this article.
References (9)
- et al.
Surgical management of morbid obesity
Curr Probl Surg
(2008) - et al.
Emerging technology: endoluminal treatment of obesity
Gastrointest Endosc
(2009) - et al.
First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve
Surg Obes Relat Dis
(2008) - et al.
Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates
Gastrointest Endosc
(2010)
Cited by (40)
Bariatric and metabolic endoscopy. State of the art and future
2023, Nutrition Clinique et MetabolismePhysiology Reconfigured: How Does Bariatric Surgery Lead to Diabetes Remission?
2023, Endocrinology and Metabolism Clinics of North AmericaCitation Excerpt :Although the longer device has been trialed in humans,68 the device has not been studied in preclinical models like the duodenojejunal sleeve barrier. Like animal models, human studies demonstrate weight loss and improvement in HbA1c.69,70 Similar approaches to the endoluminal liner include a pharmacologic “coating of the mucosa” with a sucrose-based, octasulfate aluminum complex.71
Medical Devices in the Treatment of Obesity
2016, Endocrinology and Metabolism Clinics of North AmericaCitation Excerpt :Candidates for such therapy may include those with severe comorbid conditions precluding surgery or the supermorbid obese patients who may need a bridge to definitive surgical therapy. This concept of “downstaging” patients before undergoing definitive bariatric surgery8 is a proven concept and has been shown to aid in ease of operation by decreasing liver size and visceral fat stores. In addition, there are many patients who simply do not want surgical treatment of their obesity.
Obesity and diabetes mellitus in the Arab world
2016, Journal of Taibah University Medical SciencesGastrointestinal devices for the treatment of type 2 diabetes
2016, Surgery for Obesity and Related DiseasesCitation Excerpt :There are also gut hormonal changes that induce satiety, specifically an increase in PYY 3-36, similar to Roux-en-Y gastric bypass. Weight loss with this device has been reported to be 11.9–32 %EWL [13,14]. In addition, exclusion of duodenal-jejunal nutrient flow (as with the gastric bypass) is associated with improvements in glycemic control for diabetic patients.
Hepatic abscess as a complication of duodenal-jejunal bypass sleeve system and review of the literature
2016, Surgery for Obesity and Related Diseases